SEATTLE, WA, USA/EINPresswire.com/ — Healionics Corporation, a developer of biomaterial-based medical devices, today announced the close of a $5.5 million equity financing round led by Keiretsu Capital with participation by several prominent angel groups. The funds will be used to complete an ongoing human trial and to pursue regulatory clearance and commercialization of Healionics’ novel STARgraft vascular graft.
Healionics Closes $5.5 Million Series A-3 Financing Round
